

Supplementary Table S1. The estimated 5-year DFS and 5-year OS of osteosarcoma patients by the Flexible parametric survival model.

Prognostic factors	5-year disease free survival		5-year overall survival	
	aHR (95% CI)	p value	aHR (95% CI)	p value
Gender				
Female	0.33 (0.16-0.72)	0.005	0.41 (0.20-0.87)	0.019
Male	(ref.)		(ref.)	
Age group (years)				
≥ 18 years	0.60 (0.26-1.37)	0.224	0.64 (0.51-2.14)	0.269
< 18 years	(ref.)		(ref.)	
Resectable	0.17 (0.07-0.40)	<0.001	0.21 (0.09-0.50)	<0.001
Unresectable/metastasis	(ref.)		(ref.)	
Received neoadjuvant chemotherapy				
TNR ≥ 90%	0.08 (0.01-0.62)	0.016	0.09 (0.01-0.74)	0.024
TNR 50-89%	2.37 (0.84-6.73)	0.105	1.59 (0.58-4.34)	0.365
TNR < 50%	0.58 (0.23-1.48)	0.257	0.71 (0.29 -1.69)	0.436
Not received neoadjuvant chemotherapy	(ref.)		(ref.)	
Radiation therapy	1.47 (0.71-3.01)	0.319	1.38 (0.66-2.85)	0.338

Abbreviations: aHR, Adjusted hazard ratio; TNR, Tumor necrosis rate (post neoadjuvant chemotherapy).

Supplementary Table S2. The estimated 5-year DFS and 5-year OS of Ewing's sarcoma patients by the Flexible parametric survival model.

Prognostic factors	5-year disease free survival		5-year overall survival	
	aHR (95% CI)	p value	aHR (95% CI)	p value
Gender				
Female	0.46 (0.14-1.49)	0.194	0.69 (0.19-2.46)	0.566
Male	(ref.)		(ref.)	
Age group (years)				
≥ 25 years	6.05 (1.46-25.10)	0.013	6.79 (1.33-34.72)	0.021
< 25 years	(ref.)		(ref.)	
Resectable				
Resectable	0.16 (0.04-0.67)	0.012	0.06 (0.01-0.51)	0.010
Unresectable/metastasis	(ref.)		(ref.)	
Radiation therapy				
Radiation therapy	0.49 (0.14-1.66)	0.253	0.36 (0.08-1.62)	0.183

Abbreviations: aHR, Adjusted hazard ratio; CMT, chemotherapy.